FT-018
Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
UnknownActive
Key Facts
Indication
Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
Phase
Unknown
Status
Active
Company
About Frontera Therapeutics
Frontera Therapeutics is an emerging, international gene therapy company with a dual focus on innovative rAAV technology and efficient manufacturing. The company has built two proprietary platforms: EXACTE™ for vector design and AAVANCE™ for scalable, low-cost GMP production. Several of its programs, including FT-001 and FT-002, have advanced into Phase II clinical trials with regulatory designations, positioning the company competitively in key therapeutic areas. With R&D in Boston, operations in Shanghai, and manufacturing in Suzhou, Frontera is structured for global development.
View full company profile